NEOGENOMICS, INC. (NASDAQ:NEO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 19, 2017, the board of directors (the “Board”) of NeoGenomics, Inc. (the “Company”) accepted the resignation of Kieran Murphy as a member of the Board effective immediately.Mr. Murphy, who was appointed to the Board on February 17, 2016 and served on the Nominating and Corporate Governance and Compensation Committees of the Board, was appointed President and Chief Executive Officer, GE Healthcare, a business unit of General Electric, on June 12, 2017.Mr. Murphy’s resignation as a member of the Board was based on the time commitment required in his new position with General Electric.
On July 19, 2017, the Board also appointed Stephen Kanovsky to serve as a member of the Board effective immediately to fill the vacancy created by Mr. Murphy’s resignation.This appointment was to the Investor Board Rights, Lockup and Standstill Agreement (the “Investor Board Rights Agreement) under which the Company is required to appoint a director designated by GE Medical Systems to the Board.Mr. Kanovsky, who was appointed as a Board observer on February 17, 2016, was recommended by Mr. Murphy for approval by the Nominating and Corporate Governance Committee of the Board to the Investor Board Rights Agreement.It is anticipated that Mr. Kanovsky will also serve on the Nominating and Corporate Governance and Compensation Committees of the Board.
Mr. Kanovsky is General Counsel, Global Innovation of GE Healthcare, a business unit of General Electric that provides medical technologies and solutions to the global healthcare industry and supports customers in over 100 countries with a broad range of services and systems, from diagnostic imaging and healthcare IT through to molecular diagnostics and life sciences.Mr. Kanovsky has over 23 years of legal experience in the global life sciences and biotechnology industry.Mr. Kanovsky earned his bachelor’s degree in 1984 from the University of Pennsylvania.He subsequently graduated from Temple University’s School of Pharmacy with a master’s degree in Pharmacology and Temple University’s School of Law with a juris doctorate degree.Mr. Kanovsky also holds a master’s degree in business administration from Saint Joseph’s University’s Haub School of Business.
|
Item 5.02. |
Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
Description |
|
10.1 |
Investor Board Rights, Lockup and Standstill Agreement, dated December30, 2015, by and between NeoGenomics, Inc. and GE Medical Systems Information Technologies, Inc. (filed as Exhibit10.1 to the Current Report on Form8-K filed with the SEC on December 31, 2015 and incorporated herein by reference). |
About NEOGENOMICS, INC. (NASDAQ:NEO)
NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. Its Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The Company offers testing services, which includes Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations, and immunohistochemistry (IHC), and digital imaging, which is a process of localizing proteins in cells of a tissue section and relies on the principle of antibodies binding specifically to antigens in biological tissues.